Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by multiorgan involvement and immunological abnormalities that include aberrant autoreactive B cell responses. In SLE, elevated levels of autoantibodies, particularly those recognizing double-stranded DNA, are considered to be pathogenic (Kotzin, 1996; Arbuckle et al., 2003), as autoantibody-derived immune complexes deposit in tissues and exacerbate SLE disease pathogenesis, such as lupus nephritis (Koffler et al., 1971).

The mechanisms underlying the failure to maintain B cell tolerance in SLE remain incompletely understood. There are multiple checkpoints during B cell development, maturation, and activation that have been demonstrated to be defective in mouse lupus models (Kuo et al., 1999; Grimaldi et al., 2001, 2002; Santulli-Marotto et al., 2001) as well as in SLE patients (Wardemann et al., 2003; Cappione et al., 2005; Yurasov et al., 2005, 2006). Thus, active SLE patients show elevated frequencies of autoreactive B cells in the new emigrant and mature B cell compartments (Pugh-Bernard et al., 2001; Yurasov et al., 2005, 2006). SLE patients in clinical remission continue to show higher numbers of autoreactive mature naive B cells, although at lower frequency than patients with active disease. Thus, the treatments do not seem to restore defective early B cell tolerance checkpoints in this disease. The frequency of polyreactive IgG+ memory B cells from untreated, active SLE patients seems to be similar to those of healthy controls, but at higher frequency of SLE, autoantigen-specific cells exist within this compartment in some patients (Mietzner et al., 2008). Altered tolerance checkpoints have also been described in the lymphoid organs of SLE patients, as autoreactive B cells are allowed to undergo germinal center reaction in tonsils (Cappione et al., 2005). In addition, SLE patient blood is characterized by...
B cell lymphopenia and alterations in B cell subset composition. Thus, numbers of naïve B cells are decreased, whereas the frequency of CD27− memory B cells, plasmablasts (PBs), and plasma cells (PCs) is increased (Odendahl et al., 2000; Arce et al., 2001; Wei et al., 2007). However, the mechanisms underlying these alterations are not well understood.

DCs play an important role in B cell activation (Dubois et al., 1997; Jego et al., 2003) as well as in B cell tolerance (Pascual et al., 2003; Banchereau et al., 2004). Constitutive deletion of DCs in a mouse lupus model led to disease improvement (Teichmann et al., 2010), whereas their deletion in a nonautoimmune model resulted in autoimmunity (Ohnmacht et al., 2009). DCs circulate at very low levels in the blood of SLE patients (Blanco et al., 2001), and thus their ex vivo functional properties are difficult to study. Monocytes represent the most abundant circulating pool of APCs and also serve as precursors of macrophages and DCs. Indeed, blood monocytes from pediatric SLE patients act as DCs, as they induce the proliferation of allogeneic naïve CD4+ T cells (Blanco et al., 2001). Furthermore, exposure of healthy monocytes to SLE serum results in the generation of DCs with DC morphology and functions. This DC-inducing property of SLE serum is mainly mediated through IFN-α (Blanco et al., 2001). However, SLE serum contains additional factors that might potentiate healthy monocyte differentiation into DCs (Gill et al., 2002) and eventually promote autoreactive B cell responses in patients.

In this study, we have explored the capability of SLE serum–induced monocyte-derived DCs (SLE-DCs) to promote B cell responses. Our data demonstrate that SLE-DCs are very efficient at inducing naïve and memory B cell differentiation into IgG− and particularly IgA-secreting PBs through conventional as well as novel pathways. Furthermore, blood monocytes of SLE patients showed similar functional characteristics to those of SLE-DCs. Understanding the mechanisms underlying SLE-DC–mediated B cell responses might disclose novel therapeutic targets to treat this disease.

RESULTS
Phenotype and morphology of SLE-DCs
SLE serum induces the differentiation of healthy monocytes into DCs in an IFN-α–dependent manner (Blanco et al., 2001). Thus, we first compared the phenotype of DCs generated by culturing healthy monocytes with either SLE serum (SLE-DCs) or IFN-α plus GM-CSF (IFN-DCs). Both SLE-DCs and IFN-DCs expressed comparable levels of HLA-DR and CD80, but SLE-DCs expressed higher levels of CD14 and CD86 (Fig. 1 A). Although this phenotype was consistent regardless of the method used to purify monocytes, neither IFN-DCs nor SLE-DCs expressed significant levels of CD83 unless monocytes were obtained by CD14 positive selection, as previously reported (Gill et al., 2002). Notably, whereas a fraction of SLE-DCs expressed CCR5 and CD163, IFN-DCs expressed low levels of CD163. Additionally, a fraction of IFN-DCs expressed CD1a (Fig. 1 A); this marker was absent on SLE-DCs. Fig. 1 B shows the percentage of CD1a+, CCR5+, and CD163+ cells in IFN-DCs and SLE-DCs.

Giemsa staining of SLE-DCs showed the presence of dendrites. As compared with the fine projections of dendrites found in IFN-DCs, SLE-DCs had a mixture of fine and thicker dendrites (SLE-DCs 1 and SLE-DCs 2) and contained larger numbers of cytoplasmic vacuoles (Fig. 1 C). Thus, SLE-DCs...
differ from IFN-DCs with respect to phenotype and morphology. This raised the question as to whether the two types of DCs possess distinct functions in the controlling of B cell responses.

SLE-DCs induce naive B cells to differentiate into IgG- and IgA-secreting PBs

To test the role of SLE-DCs on B cell responses, purified naive B cells (CD19+IgD+CD27+) were cultured with or without DCs in the presence of IL-2 and CpG. It is known that CpG promotes memory B cell proliferation and IgM production (Krieg et al., 1995; Bernasconi et al., 2002). CpG can also activate naive human B cells (He et al., 2004; Huggins et al., 2007; Jiang et al., 2007), resulting in enhanced proliferation and survival. However, CpG alone does not induce IgG or IgA class switching (He et al., 2004; Jiang et al., 2007). IL-2 supports human B cell proliferation and Ig production (Yoshizaki et al., 1982; Arpin et al., 1995).

SLE-DCs and IFN-DCs were equally effective at enhancing the proliferation of naive B cells (Fig. 2, A and B). They also equally supported the differentiation of PBs (Fig. 2, A and C), as measured by up-regulation of CD38 and down-regulation of CD20 expression. Although IFN-DCs and SLE-DCs were equally potent at inducing IgM secretion, SLE-DCs were more potent than IFN-DCs at inducing naive B cells to secrete switched isotypes, especially IgA (Fig. 2 D). This was further confirmed by intracellular Ig staining (Fig. 2 E). The lower capability of IFN-DCs to promote IgG and IgA was not caused by a defect in AID (activation-induced cytidine deaminase) expression, as AICDA expression levels were similar in B cells co-cultured with either type of DCs (Fig. 2 F).

RT-PCR analysis of switch circle transcripts revealed that naive B cells co-cultured with either IFN-DCs or SLE-DCs had significantly increased levels of Γ-3Cμ. (Fig. 2 G). Naive B cells co-cultured with SLE-DCs but not IFN-DCs showed increased levels of IgA class switching as measured by Igα-Cμa transcripts. Additionally, B cells co-cultured with SLE-DCs showed higher levels of the mature transcripts VΔ1(Dμ1–Cμγ1) and VΔ3(Dμ3–Cμα3) than B cells co-cultured with IFN-DCs (Fig. 2 H). Compared with B cells alone, IFN-DCs also increased expression of VΔ3(Dμ3–Cμα3) and VΔ1(Dμ1–Cμγ1) transcripts. Collectively, SLE-DCs display a potent capability to enhance naive B cell differentiation into IgG- and IgA-PBs. Although SLE sera contain elevated levels of IL-21 (0.05–2 ng/ml; Kang et al., 2011), 1–100 ng/ml of exogenous IL-21 did not further enhance the SLE-DC-mediated naive B cell responses in the presence of IL-2 and CpG (not depicted).

SLE-DCs enhance IgG and IgA secretion from memory B cells and support PB survival

We then tested whether SLE-DCs could promote the differentiation of both CD19+IgD+CD27+ and CD19+IgD−CD27+ memory B cells into PBs. As shown in Fig. 3 A, SLE-DCs efficiently induced IgD−CD27+ B cell differentiation into PBs (CD20−CD38+) secreting IgG and IgA. In particular, SLE-DCs were more efficient than IFN-DCs at inducing IgA-secreting B cell responses. Similar to IgD−CD27+ B cells, IgD−CD27+ memory B cells co-cultured with SLE-DCs secreted increased levels of IgG and particularly IgA (Fig. 3 B). Thus, SLE-DCs can efficiently promote both naive and memory B cell responses.

We next tested the effect of SLE-DCs on PB survival. PBs were generated by co-culturing purified total B cells and conventional monocyte-derived IL-4–DCs (monocytes cultured with GM-CSF and IL-4). These PBs were composed of IgM− (~35%), IgG− (~37%), and IgA−PBs (~16%), as measured by surface Ig staining (not depicted). FACS-sorted total PBs (CD20−CD38+) were further cultured with or without SLE-DCs in the presence of IL-2 only. SLE-DCs enhanced the number of viable PBs by more than sevenfold (Fig. 3 C) and resulted in enhanced Ig secretion (not depicted). PBs exposed to SLE-DCs displayed increased levels of Bcl-2, whereas Bcl-2 levels were not altered (Fig. 3 D). Thus, SLE-DCs can enhance B cell responses by promoting the differentiation of naive and memory B cells into PBs and by supporting PB survival and Ig secretion.

SLE-DC-mediated IgG and IgA responses are differentially regulated by B cell–activating factor (BAFF)/IL-10 and a proliferation–inducing ligand (APRIL), respectively

To understand the mechanisms whereby SLE-DCs promote IgG and IgA secretion, we tested the effects of BAFF (TNFSF13B) and APRIL (TNFSF13) on naive B cells. Both BAFF and APRIL support B cell survival as well as Ig class switching (Litinskiy et al., 2002; Xu et al., 2007). Furthermore, SLE patient serum displays elevated levels of BAFF and APRIL (Cheema et al., 2001; Koyama et al., 2005). Fig. 4 A shows that IFN-DCs and SLE-DCs, but not monocytes from healthy donors, constitutively secrete both APRIL and BAFF. In addition, SLE serum up-regulates BAFF and APRIL gene expression in monocytes in a type I IFN–dependent and –independent manner, respectively (unpublished data).

To test the effects of DC-derived BAFF and APRIL on naive B cell responses, anti-BAFF antibody and TACI-Fc were added to the 12-d co-culture of DCs and naive B cells in the presence of IL-2 and CpG. Anti-BAFF antibody neutralizes only BAFF, whereas TACI-Fc neutralizes both BAFF and APRIL. Interestingly, anti-BAFF antibody reduced the levels of IgG produced in co-cultures, whereas TACI-Fc reduced both IgM and IgA levels (Fig. 4 B, top). In contrast, neither anti-BAFF antibody nor TACI-Fc significantly altered the Ig secretion of naive B cells co-cultured with IFN-DCs (Fig. 4 B, bottom). The effect of TACI-Fc or BCMA-Fc on IgG responses could not be assessed because these reagents were recognized by the anti-human IgG antibody used in the ELISA. The amount (10 μg/ml) of anti-BAFF and recombinant proteins used in this study was predetermined in separate experiments (Fig. S1). 10 μg/ml TACI-Fc efficiently decreased IgM and IgA secretion from B cells (Fig. S1 A, left and right). 10 μg/ml anti-BAFF also resulted in the least amount of IgG production (Fig. S1 A, middle). In addition, anti-BAFF
or TACI-Fc did not significantly decrease SLE-DC-mediated B cell proliferation (Fig. S1 B) but decreased the total number of B cells acquired at the end of cultures (Fig. S1 C).

Along with BAFF and APRIL, DCs can secrete other cytokines providing B cell help, such as IL-10 and IL-6. Supernatants from co-cultures of naive B cells with the two types of DCs contained similar levels of IL-10 (Fig. 4 C). To access the sources of IL-10 in the co-culture, cells were stained for intracellular cytokine expression. Fig. 4 D shows that neither IFN-DCs nor SLE-DCs alone expressed IL-10 or IL-6.

![Figure 2](https://example.com/figure2.jpg)
secretion of IgG from the co-culture of IFN-DCs and naive B cells (Fig. 4 B, bottom). Combining anti-BAFF with either TACI-Fc or anti–IL-10 did not result in any synergistic inhibition of IgA or IgG production, respectively, in the co-cultures of naive B cells and SLE-DCs (not depicted). Blocking IL-6 with anti–IL-6 and IL-6R antibodies did not significantly alter IgG responses. This might be because of the fact that anti–IL-6/IL-6R cannot efficiently block intracellularly expressed IL-6 that is used by B cells (Burdin et al., 1995).

To further explore the roles of BAFF and IL-10 in naive B cell responses, BCR-activated naive B cells were cultured with combinations of exogenous IL-10 and BAFF in the presence of IL-2 and CpG. In the presence of 20 ng/ml IL-10, BAFF did not show significant effects on naive B cell differentiation into PBs (Fig. 5 A), but the numbers of B cells acquired on day 6 were slightly increased by the increasing secretion of IgG from the co-culture of IFN-DCs and naive B cells (Fig. 4 B, bottom). Combining anti-BAFF with either TACI-Fc or anti–IL-10 did not result in any synergistic inhibition of IgA or IgG production, respectively, in the co-cultures of naive B cells and SLE-DCs (not depicted). Blocking IL-6 with anti–IL-6 and IL-6R antibodies did not significantly alter IgG responses. This might be because of the fact that anti–IL-6/IL-6R cannot efficiently block intracellularly expressed IL-6 that is used by B cells (Burdin et al., 1995).

To further explore the roles of BAFF and IL-10 in naive B cell responses, BCR-activated naive B cells were cultured with combinations of exogenous IL-10 and BAFF in the presence of IL-2 and CpG. In the presence of 20 ng/ml IL-10, BAFF did not show significant effects on naive B cell differentiation into PBs (Fig. 5 A), but the numbers of B cells acquired on day 6 were slightly increased by the increasing...
This supports the important roles of APRIL without or with BAFF in the enhanced IgM and IgA responses, which were mediated by SLE-DCs.

SLE-DCs trans-present CD138-bound APRIL to B cells to enhance IgA responses

Although SLE-DCs express APRIL (Fig. 4 A), the amount of soluble APRIL is small compared with what is found in SLE serum (Cheema et al., 2001; Koyama et al., 2005). This led us to consider that APRIL might remain cell bound. Heparan sulfate proteoglycans (HSPGs; Hendriks et al., 2005; Ingold et al., 2005; Moreaux et al., 2009), such as syndecan-1 (CD138), are expressed on PCs and bind APRIL. Indeed, we found that SLE-DCs but not IFN-DCs express CD138 (Fig. 6 A, top) as well as membrane-bound APRIL (Fig. 6 A, bottom).
Thus, we conclude that SLE serum induces CD138 expression on SLE-DCs in an IFN-independent manner. This may allow SLE-DCs to trans-present APRIL to promote B cell responses in SLE.

To test whether such membrane-bound APRIL is functional, SLE-DCs were exposed to exogenous APRIL for 30 min, washed out, and co-cultured with naive B cells in the presence of IL-2 and CpG. APRIL-fed SLE-DCs resulted in enhanced naive B cell proliferation (Fig. 6 F, left and top right) and PB differentiation (Fig. 6 F, left and bottom right). In addition, APRIL-fed SLE-DCs displayed an enhanced ability to induce IgA but not IgG or IgM secretion by activated naive B cells (Fig. 6 G). These findings were further established by blocking membrane-bound APRIL with TACI-Fc (Fig. 6, H and I). APRIL-fed SLE-DCs were incubated with TACI-Fc for 30 min and washed to remove unbound TACI-Fc before they were co-cultured with naive B cells. Accordingly, SLE-DCs but not IFN-DCs could efficiently capture and display exogenous APRIL on their surface in a dose-dependent manner (Fig. 6 B). This binding is specific, as preincubation of APRIL with HSPGs diminished the binding of APRIL to the surface of DCs (Fig. 6 C, bottom). IFN-DCs did not express significant levels of surface CD138 (Fig. 6 A), and thus the preincubation of APRIL with HSPGs did not alter the surface APRIL expression (Fig. 6 C, top). Furthermore, treatment of SLE-DCs with anti-CD138 antibody but not with an isotype control antibody resulted in decreased binding of exogenous APRIL to the surface of SLE-DCs (Fig. 6 D). Consequently, preincubation of APRIL with soluble CD138 resulted in decreased binding of exogenous APRIL to these cells (Fig. 6 E). More than 10 µg/ml of soluble CD138 did not further enhance the inhibition of APRIL binding to the cells. IFN-α did not induce CD138 expression on monocytes, as IFN-DCs do not express CD138 (Fig. 6 A). Thus, we conclude that SLE serum induces CD138 expression on SLE-DCs in an IFN-independent manner. This may allow SLE-DCs to trans-present APRIL to promote B cell responses in SLE.

To test whether such membrane-bound APRIL is functional, SLE-DCs were exposed to exogenous APRIL for 30 min, washed out, and co-cultured with naive B cells in the presence of IL-2 and CpG. APRIL-fed SLE-DCs resulted in enhanced naive B cell proliferation (Fig. 6 F, left and top right) and PB differentiation (Fig. 6 F, left and bottom right). In addition, APRIL-fed SLE-DCs displayed an enhanced ability to induce IgA but not IgG or IgM secretion by activated naive B cells (Fig. 6 G). These findings were further established by blocking membrane-bound APRIL with TACI-Fc (Fig. 6, H and I). APRIL-fed SLE-DCs were incubated with TACI-Fc for 30 min and washed to remove unbound TACI-Fc before they were co-cultured with naive B cells.

Figure 5. IL-10 promotes naive B cell differentiation into PBs and Ig secretion, whereas BAFF supports B cell survival. (A) 10^4/well BCR-activated CFSE-labeled naive B cells were cultured for 6 d in the presence of different concentrations of IL-10 and BAFF. Proliferation and PB differentiation were assessed by FACS. (B) On day 12, total Ig in the supernatants was assessed by ELISA. Error bars indicate mean ± SD of triplicate assay. Representative data from two independent experiments using cells from two healthy controls are presented. Both experiments showed similar results. In all experiments, 20 U/ml IL-2 and 50 nM CpG were added to the culture.

Accordingly, SLE-DCs but not IFN-DCs could efficiently capture and display exogenous APRIL on their surface in a dose-dependent manner (Fig. 6 B). This binding is specific, as preincubation of APRIL with HSPGs diminished the binding of APRIL to the surface of DCs (Fig. 6 C, bottom). IFN-DCs did not express significant levels of surface CD138 (Fig. 6 A), and thus the preincubation of APRIL with HSPGs did not alter the surface APRIL expression (Fig. 6 C, top). Furthermore, treatment of SLE-DCs with anti-CD138 antibody but not with an isotype control antibody resulted in decreased binding of exogenous APRIL to the surface of SLE-DCs (Fig. 6 D). Consequently, preincubation of APRIL with soluble CD138 resulted in decreased binding of exogenous APRIL to these cells (Fig. 6 E). More than 10 µg/ml of soluble CD138 did not further enhance the inhibition of APRIL binding to the cells. IFN-α did not induce CD138 expression on monocytes, as IFN-DCs do not express CD138 (Fig. 6 A). Thus, we conclude that SLE serum induces CD138 expression on SLE-DCs in an IFN-independent manner. This may allow SLE-DCs to trans-present APRIL to promote B cell responses in SLE.

To test whether such membrane-bound APRIL is functional, SLE-DCs were exposed to exogenous APRIL for 30 min, washed out, and co-cultured with naive B cells in the presence of IL-2 and CpG. APRIL-fed SLE-DCs resulted in enhanced naive B cell proliferation (Fig. 6 F, left and top right) and PB differentiation (Fig. 6 F, left and bottom right). In addition, APRIL-fed SLE-DCs displayed an enhanced ability to induce IgA but not IgG or IgM secretion by activated naive B cells (Fig. 6 G). These findings were further established by blocking membrane-bound APRIL with TACI-Fc (Fig. 6, H and I). APRIL-fed SLE-DCs were incubated with TACI-Fc for 30 min and washed to remove unbound TACI-Fc before they were co-cultured with naive B cells.
Figure 6. SLE-DCs express surface CD138 that trans-presents APRIL to B cells to enhance IgA-secreting B cell responses. (A) CD138 (top) and APRIL (bottom) expression on the surface of DCs. Closed gray histograms indicate isotype control antibody, and black line histograms indicate anti-CD138 (top) and anti-APRIL (bottom) antibody. Experiments using sera from 10 patients and monocytes from 16 healthy donors showed similar results. (B) Exogenous APRIL captured on the surface of DCs was determined by flow cytometry. Combined data (mean ± SD) from experiments using SLE-DCs made with sera from eight patients and four healthy controls are presented. (C) A competition assay was performed using 100 µg/ml HSPGs 2 h before the addition of APRIL to the DCs. Experiments using SLE-DCs made with sera from eight patients and four healthy controls showed similar results. (D) SLE-DCs were incubated with different concentrations of anti-CD138 antibody for 30 min and loaded with 2 µg/ml APRIL for 30 min. Cells were then stained with anti-APRIL antibody. (E) Differentiation and proliferation were measured (left). Combined data from experiments (right) using sera from 12 patients and cells from 6 healthy donors are presented. Student’s t test: *, P < 0.05; **, P < 0.01.
SLE monocytes express CD138 and trans-present membrane-bound APRIL to promote IgA responses

Subsets of monocytes (G1, CD14^high^CD16^-; G2, CD14^high^CD16^low^; and G3, CD14^low^CD16^high^; Fig. 8 D, top) from SLE patients and healthy controls were stained for the surface expression of CD138 and APRIL. None of the three subsets of monocytes from healthy donors expressed either of these molecules on their surface (Fig. 8 D, bottom left). In contrast, monocytes from SLE patients showed three different patterns of surface CD138 and APRIL expression (Fig. 8 D, bottom right three panels): only a fraction of monocytes (I), all populations of monocytes (II), and none (III). More importantly, we found that the percentage of APRIL^+ monocytes correlates with disease activity as measured by the SLE disease activity index (SLEDAI; Fig. 8 E). Furthermore, monocytes were able to induce naive B cells to isotype switch and to secrete Igs. Blocking membrane-bound APRIL with TACI-Fc significantly decreased IgM and IgA responses (Fig. 8 F). Blocking IL-10 also decreased IgG responses. We were also able to detect both CD138 and APRIL expression on the surface of myeloid DCs in the blood of SLE patients (not depicted). However, the numbers of DCs in the small volumes (~10–15 ml) of blood from pediatric patients did not allow us to test their functions. Collectively, our data demonstrate that SLE patient blood monocytes express CD138 and particularly IgA responses.

DISCUSSION

Autoantibodies are a hallmark of SLE, and B cells remain one of the main therapeutic targets in this disease. Our study demonstrated for the first time that SLE serum induces healthy monocyte differentiation into DCs with a unique ability to promote B cell responses. In particular, SLE-DCs and monocytes from the blood of SLE patients could efficiently generate antibody-secreting PBs, reminiscent of those found in the
blood of SLE patients. Thus, SLE serum represents a unique microenvironment for the generation of DCs that could play a role in SLE pathogenesis through interactions with B cells.

IFN-α is a key player contributing to the differentiation of SLE serum–exposed monocytes into DCs (Blanco et al., 2001). However, DCs generated with IFN–α, IFN-DCs, were phenotypically and functionally distinct from SLE-DCs. For example, >50% of the SLE-DCs express CD163 and CCR5, but low numbers of IFN-DCs (<10%) express the two surface molecules. CCR5 is known to be important in disease progression in lupus nephropathy as well as in other glomerular diseases and can be found elevated on the surface of DCs in autoimmune disorders (Furuichi et al., 2000; Stasikowska et al., 2007). It is also expressed on CD14+CD16+ human monocytes, which have been described in the renal interstitium of SLE patients (Furuichi et al., 2000; Stasikowska et al., 2007).

![Figure 8](image.png)

**Figure 8.** SLE patient monocytes express CD138 and can trans-present APRIL to B cells to expand IgA+ and IgG+ PBs. PBMCs were isolated from healthy controls and SLE patients. (A) Percentage of CD19hiCD20−CD38+ cells was assessed by flow cytometry. Combined data (mean ± SD) from 16 healthy controls and 22 SLE patients are presented. (B) Surface Ig on the CD19hiCD20− populations. Representative data from a total of 16 healthy controls and 22 SLE patients are presented. Individual experiments showed similar results. (C) Combined data (mean ± SD) from 10 healthy controls and 20 SLE patients. ANOVA test: *, P < 0.05; **, P < 0.01. (D, top) Gating strategy for blood monocytes. (bottom) Expression of CD138 and APRIL on the surface of monocyte subsets in the blood of healthy controls and SLE patients. Closed gray histograms indicate isotype control antibody, and black line histograms indicate anti-CD138 (first row) and anti-APRIL (second row) antibody. Representative data from experiments using blood from 6 healthy donors and 14 SLE patients are presented. (E) Correlation between the percentage of APRIL+ total monocytes and SLEDAI. Data from experiments using 20 patients are summarized. (F) Naive B cells were co-cultured for 12 d with patient monocytes in the presence of 10 µg/ml antibodies. 50 nM CpG and 20 U/ml IL-2 were added to the co-culture. Monocytes were incubated with 10 µg/ml TACI-Fc for 30 min and washed twice before adding to the culture. Total Ig levels were assessed by ELISA. Combined data (mean ± SD) from experiments using sera from 11 patients and cells from 6 healthy donors are presented. Student’s t test: *, P < 0.05.
Other studies have also shown elevated levels of the CCR5 ligands RANTES and MIP-1α in the kidneys and serum of SLE patients (Lit et al., 2006; Staskiwaska et al., 2007; Vila et al., 2007). CD163 is a scavenger receptor (Van Gorp et al., 2010) that might contribute to the removal of apoptotic cells. Whether CD163 expression plays a role in disease, such as favoring the presentation of apoptotic cell–derived antigens by SLE-DCs, needs to be further studied.

Although IFN-DCs and SLE-DCs were able to induce the proliferation of B cells and their differentiation into PBs, SLE-DCs were more efficient than IFN-DCs at inducing switched B cell responses, especially IgA-secreting B cell responses. The enhanced IgG responses by IFN-DCs and SLE-DCs were mainly dependent on IL-10 and IL-10/BAFF, respectively. The ability of SLE-DCs to induce IgA secretion was further linked to their surface expression of CD138, which enables the trans-presentation of APRIL to B cells. More importantly, SLE blood monocytes also expressed CD138 and trans-presented APRIL to B cells, resulting in the promotion of IgA responses. CD138 expressed on PCs has been described as an APRIL–binding partner, which is the prerequisite for the triggering of TACI– and/or BCMA–mediated PC survival (Ingold et al., 2005). CD138-bound APRIL on the surface of PCs can create unique niches that support the accumulation of PCs in mucosal surfaces (Huard et al., 2008). We found that APRIL trans-presented by SLE-DCs was efficient at enhancing IgA-secreting B cell responses. Soluble APRIL directly added to B cells only resulted in IgM secretion, supporting the idea that trans-presentation of APRIL through CD138 is one of the key mechanisms responsible for SLE-DC–mediated IgA switching and PB differentiation. This is consistent with the requirement of SLE-DCs to be in direct contact with B cells for these effects to be observed.

Although the pathogenic role of SLE IgG autoantibodies is well described, the contribution of IgA to disease pathogenesis remains largely unknown. A previous study has described a profound increase of serum IgA level in lupus patients compared with controls (Conley and Koopman, 1983). Of interest, IgA from some patients has been reported to display a lower degree of glycosylation compared with controls, which has been linked to the pathogenic nature of this isoform in a related disease, IgA nephropathy (Donadio et al., 1978; Matei and Matei, 2000–2001). Furthermore, deposits of IgA are found in the kidneys of patients with SLE (Florquin et al., 2001). Although not currently used as an inclusion criteria for SLE, IgA autoantibodies, such as anticitrullinated and anti–β2-glycoprotein-I, have been shown to predict disease manifestations such as pro-Thrombotic events (Wilson et al., 1998; Kumar et al., 2009; Sweiss et al., 2010; Mehrani and Petri, 2011a,b). In addition, the lupus-prone B6.Sle1Sle3 mouse strain produces high levels of anti-nuclear IgA autoantibodies that are deposited in the kidney glomeruli and are implicated in the pathogenesis of nephritis (Liu et al., 2007). Although selective IgA deficiency does not preclude the development of SLE, there is not enough data to ascertain whether IgA-deficient SLE patients could be excluded from suffering certain clinical manifestations such as nephritis and/or display a unique disease course.

The contribution of BAFF to B cell–mediated autoimmune diseases is relatively well understood. Excessive BAFF expression leads to autoimmunity in mice (Mackay et al., 1999; Gross et al., 2000). Elevated levels of BAFF in SLE serum support autoreactive naïve B cell (Stohl et al., 2003) and PC survival (Schneider, 2005), which is consistent with our data. Thus, blocking BAFF or BAFF/APRIL is a promising therapeutic approach to treat B cell–mediated autoimmune diseases, and drugs that block BAFF or BAFF/APRIL have been recently approved to treat SLE (Dillon et al., 2006; Sanz and Lee, 2010), although modest clinical responses were observed in phase III clinical trials. However, PBs and PCs predominantly express BCMA and TACI that bind to both BAFF and APRIL. We show that the selective blockade of BAFF reduced only IgG, whereas nonselective blockers (TACI-Fc and BCMA-Fc) also decreased IgA secretion.

The information obtained from this study is particularly relevant to the generation of extrafollicular, T-independent B cell responses (Fagarasan and Honjo, 2000; Litinska et al., 2002; Crispin et al., 2010). Studying the role of SLE serum and SLE-DCs in T-dependent B cell responses is warranted, however, as the type of DC–B cell interaction that we herein describe could also be relevant to the expansion and survival of PBs and PCs from a pool of autoreactive memory B cells initially generated in the context of T cell help. It remains to be seen whether therapies, alone or in combination, aimed at blocking these interactions will find a place in the SLE armamentarium.
IgG1 (Sigma-Aldrich) were added into B cell/DC co-culture systems. In or memory B cells and DCs. 10 µg/ml

systems). 50 nM CpG (ODN2006; InvivoGen) was added to the co-cultures nonessential amino acids, l-glutamate (Sigma-Aldrich), Pen/strep and 10%

APRIL, and BAFF. Capture and detection antibodies for Ig ELISAs were

Sandwich ELISAs were performed to measure total IgM, IgG, IgA, ELISA.

ware (Tree Star).

Cytokine ELISA and intracellular staining. 10^5 DCs were plated in a 100-µl volume and stimulated for 24 h with and without 20 ng/ml *Esherichia coli* LPS (InvivoGen). IL-10 was measured on a Luminex bead-based platform using a Bio Plex 200 and the Bio Plex Manager 5.0 software (Bio-Rad Laboratories). This system was also used to determine the concentration of IL-10 in DC–B cell co-culture systems. Both IFN-DCs and SLE-DCs were stained for intracellular IL-6 and IL-10 before co-culturing with B cells. In addition, DCs and naïve B cells were co-cultured for 24 h and then stained for intracellular IL-6 and IL-10.

Statistical analysis. Statistical significance was determined using the analysis of variance (ANOVA) and Student’s t test using Prism 5 software (GraphPad Software). Significance was set at P < 0.05.

Online supplemental material. Fig. S1 shows that TACI-Fc and anti-BAFF antibody decrease IgM and IgA as well as IgG responses, respectively, in dose-dependent manners. Table S1 presents demographics of SLE patients and healthy donors tested in this study. Online supplemental material is available at http://www.jem.org/cgi/content/full/jem.20111644/DC1.

We thank Dr. Jeanine Baisch for coordinating samples and obtaining clinical data. We thank Tracey Wright, Alisa Gotta, Loren Nasi, and Matthew Stoll for collecting patient samples at the Texas Scottish Rite Hospital for Children. We thank Nicolas Loof and colleagues in the Flow Cytometry Core, Lynnette Walters in the Cell Processing Core, and Shannon Lunt in the Sample Core at the Baylor Institute for Immunology Research (BIIR). We thank Dr. Carson Harrod for supporting this study. We thank Dr. Michael A. Ramsay for supporting this study.

This work was supported by P50-AR0 5503 (National Institutes of Health [NIH]), P50-AR0 54083 (NIH), and the Baylor Health Care System Foundation.

The authors have no competing financial interests regarding this work.

Author contributions: H. Joo, C. Coquery, Y. Xue, and S. Oh performed experiments and analyzed data. I. Gayet provided technical assistance. S.R. Dillon and M. Punaro provided reagents and patient samples, respectively. G. Zurawski, J. Banchereau, and V. Pascual analyzed data and helped with writing this manuscript. H. Joo and S. Oh provided reagents and patient samples, respectively. G. Zurawski, J. Banchereau, and V. Pascual wrote the manuscript.

Accepted: 14 May 2012

Submitted: 5 August 2011

REFERENCES


Arce, E., D.G. Jackson, M.A. Gill, L.B. Bennett, J. Banchereau, and V. Pascual. 2001. Increased frequency of pre-germinal center B cells and

Statistical significance was determined using the analysis of variance (ANOVA) and Student’s t test using Prism 5 software (GraphPad Software). Significance was set at P < 0.05.

Online supplemental material. Fig. S1 shows that TACI-Fc and anti-BAFF antibody decrease IgM and IgA as well as IgG responses, respectively, in dose-dependent manners. Table S1 presents demographics of SLE patients and healthy donors tested in this study. Online supplemental material is available at http://www.jem.org/cgi/content/full/jem.20111644/DC1.

We thank Dr. Jeanine Baisch for coordinating samples and obtaining clinical data. We thank Tracey Wright, Alisa Gotta, Loren Nasi, and Matthew Stoll for collecting patient samples at the Texas Scottish Rite Hospital for Children. We thank Nicolas Loof and colleagues in the Flow Cytometry Core, Lynnette Walters in the Cell Processing Core, and Shannon Lunt in the Sample Core at the Baylor Institute for Immunology Research (BIIR). We thank Dr. Carson Harrod for supporting this study. We thank Dr. Michael A. Ramsay for supporting this study.

This work was supported by P50-AR0 5503 (National Institutes of Health [NIH]), P50-AR0 54083 (NIH), and the Baylor Health Care System Foundation.

The authors have no competing financial interests regarding this work.

Author contributions: H. Joo, C. Coquery, Y. Xue, and S. Oh performed experiments and analyzed data. I. Gayet provided technical assistance. S.R. Dillon and M. Punaro provided reagents and patient samples, respectively. G. Zurawski, J. Banchereau, and V. Pascual analyzed data and helped with writing this manuscript. H. Joo and S. Oh wrote the manuscript.

Submitted: 5 August 2011

Accepted: 14 May 2012

REFERENCES


Arce, E., D.G. Jackson, M.A. Gill, L.B. Bennett, J. Banchereau, and V. Pascual. 2001. Increased frequency of pre-germinal center B cells and

RT-PCR. Total RNA was isolated from B cells co-cultured with DCs using the RNeasy Micro kit (Invitrogen), and cDNA was synthesized using the Reverse Transcription System (Promega). cDNA was amplified with the LightCycler SYBR Green Master I kit (Roche) according to the manufacturer’s instructions and run on a LightCycler 480 (Roche). Primers for switch circles, mature transcripts, AICDA, and β-actin were as previously described (He et al., 2007; Dullaers et al., 2009); Bcl-6 forward, 5′-AAGC-GCTGCTGGGCTTTCC-3′; Bcl-6 reverse, 5′-CTGGGACACTTTTGG-GATCTCT-3′; Bel-2 forward, 5′-TGGGAGCTCCTTTGGAAC-3′; and Bel-2 reverse, 5′-GAGACAGCCAGGAGAACTCAAC-3′. Relative expression was determined using the comparative C, method.

APRIL binding assays. DCs were incubated with a titrating dose of APRIL trimer (ZymoGenetics) for 30 min at 37°C. 50 µg/ml HSPGs (Sigma-Aldrich) was added to the DCs 30 min before the addition of APRIL. Membrane-bound APRIL was detected by anti-human APRIL antibody (Enzo Life Sciences).

Cytokine ELISA and intracellular staining. 10^5 DCs were plated in a 100-µl volume and stimulated for 24 h with and without 20 ng/ml *Esherichia coli* LPS (InvivoGen). IL-10 was measured on a Luminex bead-based platform using a Bio Plex 200 and the Bio Plex Manager 5.0 software (Bio-Rad Laboratories). This system was also used to determine the concentration of IL-10 in DC–B cell co-culture systems. Both IFN-DCs and SLE-DCs were stained for intracellular IL-6 and IL-10 before co-culturing with B cells. In addition, DCs and naïve B cells were co-cultured for 24 h and then stained for intracellular IL-6 and IL-10.

Statistical analysis. Statistical significance was determined using the analysis of variance (ANOVA) and Student’s t test using Prism 5 software (GraphPad Software). Significance was set at P < 0.05.

Online supplemental material. Fig. S1 shows that TACI-Fc and anti-BAFF antibody decrease IgM and IgA as well as IgG responses, respectively, in dose-dependent manners. Table S1 presents demographics of SLE patients and healthy donors tested in this study. Online supplemental material is available at http://www.jem.org/cgi/content/full/jem.20111644/DC1.

We thank Dr. Jeanine Baisch for coordinating samples and obtaining clinical data. We thank Tracey Wright, Alisa Gotta, Loren Nasi, and Matthew Stoll for collecting patient samples at the Texas Scottish Rite Hospital for Children. We thank Nicolas Loof and colleagues in the Flow Cytometry Core, Lynnette Walters in the Cell Processing Core, and Shannon Lunt in the Sample Core at the Baylor Institute for Immunology Research (BIIR). We thank Dr. Carson Harrod for supporting this study. We thank Dr. Michael A. Ramsay for supporting this study.

This work was supported by P50-AR0 5503 (National Institutes of Health [NIH]), P50-AR0 54083 (NIH), and the Baylor Health Care System Foundation.

The authors have no competing financial interests regarding this work.

Author contributions: H. Joo, C. Coquery, Y. Xue, and S. Oh performed experiments and analyzed data. I. Gayet provided technical assistance. S.R. Dillon and M. Punaro provided reagents and patient samples, respectively. G. Zurawski, J. Banchereau, and V. Pascual analyzed data and helped with writing this manuscript. H. Joo and S. Oh wrote the manuscript.

Submitted: 5 August 2011

Accepted: 14 May 2012

REFERENCES


Arce, E., D.G. Jackson, M.A. Gill, L.B. Bennett, J. Banchereau, and V. Pascual. 2001. Increased frequency of pre-germinal center B cells and...


Figure S1. TACI-Fc and anti-BAFF antibody decrease IgM and IgA as well as IgG responses in dose-dependent manners. (A) CFSE-labeled purified naive B cells were co-cultured with SLE-DCs for 12 d in the presence of the indicated antibodies or recombinant proteins. Total Ig levels in the supernatants were assessed by ELISA. Representative data from one experiment with triplicate assay are shown. Experiments using sera from four SLE patients and cells from four healthy donors showed similar results. (B) Proliferation. (C) Total numbers of B cells on day 6. In B and C, combined data from experiments using sera from four SLE patients and cells from four healthy donors are presented. In all experiments, 20 U/ml IL-2 and 50 nM CpG were added to the culture. Mean ± SD is shown. Student’s t test: *, P < 0.05; **, P < 0.01.

Table S1. Demographics of SLE patients and healthy donors tested in this study

<table>
<thead>
<tr>
<th>Donors</th>
<th>Gender</th>
<th>Ethnicity</th>
<th>Age (mean)</th>
<th>SLEDAI (mean)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Male</td>
<td>Female</td>
<td>C  AS  AA  H  NR</td>
<td>yr</td>
</tr>
<tr>
<td>SLE</td>
<td>18</td>
<td>78</td>
<td>11 10 26 45 4</td>
<td>14.42</td>
</tr>
<tr>
<td>Healthy</td>
<td>21</td>
<td>26</td>
<td>19 4 5 8 11</td>
<td>16.9</td>
</tr>
</tbody>
</table>

AA, African American; AS, Asian; C, Caucasian (not of Hispanic decent); H, Hispanic; NA, not applicable; NR, not reported/recorded.